MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Navidea Biopharmaceuticals DPO Ratio 2011-2026 | NAVB
Annual DPO Ratio Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 333 K | - | 405 K | 60.9 K | 1.6 K | 85.5 K | 1.13 K | 368 | 340 | 2.66 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 405 K | 340 | 98.9 K |
Quarterly DPO Ratio Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 133 K | 385 K | - | - | - | - | - | - | 1.29 M | 297 K | 170 K | - | 520 K | 426 K | 11.4 K | - | 1.02 K | 1.1 K | 184 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 1.02 K | 311 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
74.3 | $ 35.05 | 1.73 % | $ 943 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.66 | 2.16 % | $ 442 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Heron Therapeutics
HRTX
|
91.4 | $ 0.88 | 3.88 % | $ 147 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
82.7 | $ 2.62 | -3.33 % | $ 245 M | Israel |
 |
Anika Therapeutics
ANIK
|
43.4 | $ 15.05 | -0.59 % | $ 216 M | USA |
 |
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
Incyte Corporation
INCY
|
200 | $ 97.57 | 0.5 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
815 | $ 76.17 | 1.47 % | $ 12.2 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Coherus BioSciences
CHRS
|
507 | $ 1.6 | 5.63 % | $ 187 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 20.96 | 2.37 % | $ 2.67 B | USA |